331. Idiopathic multicentric castleman disease Clinical trials / Disease details
Clinical trials : 33 / Drugs : 46 - (DrugBank : 25) / Drug target genes : 31 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2071190029 | 25/05/2020 | 09/10/2019 | Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) | Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) | idiopathic multicentric Castleman's disease Castleman's disease | Treatment: Sirolimus 2 mg po once/day. Control: Placebo given orally once daily | Kawakami Atsushi | NULL | Not Recruiting | >= 18age old | Not applicable | Both | 20 | Phase 2 | Japan |
| 2 | NCT01441063 (ClinicalTrials.gov) | September 13, 2011 | 24/9/2011 | Tocilizumab for KSHV-Associated Multicentric Castleman Disease | Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman Disease | Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia | Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC) | National Cancer Institute (NCI) | NULL | Completed | 18 Years | N/A | All | 8 | Phase 2 | United States |
| 3 | NCT01183598 (ClinicalTrials.gov) | August 2006 | 13/8/2010 | A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment | Provision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab Treatment | Castleman's Disease | Drug: tocilizumab [RoActemra/Actemra] | Hoffmann-La Roche | NULL | Completed | 18 Years | N/A | Both | 3 | Phase 1 | United States |